What is MAP?
The MECFA Access Program (MAP) is a not-for-profit distribution program aimed at providing a short list of essential therapies at a substantially reduced price for CF patients in developing countries in the Middle East, North Africa and Central Asia who do not currently have access.
What will MAP do for patients?
MECFA works with CF drug companies to negotiate the lowest prices possible for essential CF drugs. As a charity, we appeal to companies' philanthropic side and work in collaboration to ensure our CF patients have access to their life-saving drugs.
We partner with health ministries to register a short list of essential CF drugs and ensure access to these drugs at affordable prices.
How does MAP work?
Think of it as a CF essential therapies Buyers Club.
MECFA supplies essential CF therapies to qualifying countries. Our list of therapies includes inhaled tobramycin, Dornase Alfa, inhaled hypertonic saline, CF vitamins, iAztreonam for inhalation, and CF specific nebulizers.
MAP supplies CF essential therapies and equipment discounted to qualifying MECFA member countries.
MAP manages registration of theapries with health ministries and local advocates.
MAP manages orders from member countries directly with pharmaceutical partners, organizes import and transfers to participating countries.
Are you interested to learn more about MAP, contact us at email@example.com.